Autopsy report · NCT03855865

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

“Business decision to stop the program.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Naurex, Inc, an affiliate of Allergan plc

Sponsor type

Industry

Conditions

Depressive Disorder, Major

Interventions

Rapastinel; Vortioxetine; Placebo

Participants

0

Trials that died the same way

• Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
  “Sponsor decision to terminate the program” (76% match in meaning)
• A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
  “Business decision to stop the study.” (72% match in meaning)
• Natural History Study of Patients With Methylmalonic Acidemia and Propionic Acidemia
  “The decision to terminate the study was based on business considerations by the Sponsor.” (63% match in meaning)
• A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
  “Sponsor stopped program\]” (62% match in meaning)
• Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
  “The Relamorelin program is being terminated solely based on a business decision” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.